Source: UroToday
Lead-212 Radiopharmaceuticals: Advancing Targeted Alpha Therapy in Oncology – Anna Karmann
Oliver Sartor interviews Anna Karmann about the potential of radiopharmaceuticals in cancer treatment. Dr. Karmann discusses the advantages of Lead-212, highlighting its alpha-emitting properties, short half-life, and potential for frequent dosing strategies.
She emphasizes the unique benefits of Lead-212, including its synergy with the immune system and logistical advantages in drug delivery. Dr. Karmann explores potential combination therapies and targets for radiopharmaceuticals, mentioning KLK2, GPC3, and DLL3 among others. She also touches on the possibility of using radiopharmaceuticals for non-oncologic diseases.
Looking to the future, Dr. Karmann predicts advancements in understanding long-term safety, earlier use of radiopharmaceuticals in treatment, innovative dosing strategies, and faster drug development processes. She expresses optimism about the field’s potential to change treatment paradigms and improve patient outcomes.
